Classical Cyclophosphamide, Methotrexate, and Fluorouracil Chemotherapy Is More Effective in Triple-Negative, Node-Negative Breast Cancer: Results From Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer

Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009

(2009) A. Goldhirsch et al.   ANNALS OF ONCOLOGY

Breast Cancer Subtypes and Response to Docetaxel in Node-Positive Breast Cancer: Use of an Immunohistochemical Definition in the BCIRG 001 Trial

(2009) Judith Hugh et al.   JOURNAL OF CLINICAL ONCOLOGY

Should we be surprised at the paucity of response to EGFR inhibitors?

(2009) Barry A Gusterson et al.   LANCET ONCOLOGY

Invasive ductal carcinoma of the breast with the “triple-negative” phenotype: prognostic implications of EGFR immunoreactivity

(2008) Giuseppe Viale et al.   BREAST CANCER RESEARCH AND TREATMENT

Chemoendocrine Compared With Endocrine Adjuvant Therapies for Node-Negative Breast Cancer: Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors—International Breast Cancer Study Group

(2008) Giuseppe Viale et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive Value of Tumor Ki-67 Expression in Two Randomized Trials of Adjuvant Chemoendocrine Therapy for Node-Negative Breast Cancer

(2008) Giuseppe Viale et al.   JNCI-Journal of the National Cancer Institute

HER2 Status and Efficacy of Adjuvant Anthracyclines in Early Breast Cancer: A Pooled Analysis of Randomized Trials

(2007) Alessandra Gennari et al.   JNCI-Journal of the National Cancer Institute